These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

521 related items for PubMed ID: 15518543

  • 1. Tumor cells resistant to a microtubule-depolymerizing hemiasterlin analogue, HTI-286, have mutations in alpha- or beta-tubulin and increased microtubule stability.
    Poruchynsky MS, Kim JH, Nogales E, Annable T, Loganzo F, Greenberger LM, Sackett DL, Fojo T.
    Biochemistry; 2004 Nov 09; 43(44):13944-54. PubMed ID: 15518543
    [Abstract] [Full Text] [Related]

  • 2. HTI-286, a synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo.
    Loganzo F, Discafani CM, Annable T, Beyer C, Musto S, Hari M, Tan X, Hardy C, Hernandez R, Baxter M, Singanallore T, Khafizova G, Poruchynsky MS, Fojo T, Nieman JA, Ayral-Kaloustian S, Zask A, Andersen RJ, Greenberger LM.
    Cancer Res; 2003 Apr 15; 63(8):1838-45. PubMed ID: 12702571
    [Abstract] [Full Text] [Related]

  • 3. Biophysical characterization of the interactions of HTI-286 with tubulin heterodimer and microtubules.
    Krishnamurthy G, Cheng W, Lo MC, Aulabaugh A, Razinkov V, Ding W, Loganzo F, Zask A, Ellestad G.
    Biochemistry; 2003 Nov 25; 42(46):13484-95. PubMed ID: 14621994
    [Abstract] [Full Text] [Related]

  • 4. The microtubule-stabilizing agent discodermolide competitively inhibits the binding of paclitaxel (Taxol) to tubulin polymers, enhances tubulin nucleation reactions more potently than paclitaxel, and inhibits the growth of paclitaxel-resistant cells.
    Kowalski RJ, Giannakakou P, Gunasekera SP, Longley RE, Day BW, Hamel E.
    Mol Pharmacol; 1997 Oct 25; 52(4):613-22. PubMed ID: 9380024
    [Abstract] [Full Text] [Related]

  • 5. beta-Tubulin mutations are associated with resistance to 2-methoxyestradiol in MDA-MB-435 cancer cells.
    Gökmen-Polar Y, Escuin D, Walls CD, Soule SE, Wang Y, Sanders KL, Lavallee TM, Wang M, Guenther BD, Giannakakou P, Sledge GW.
    Cancer Res; 2005 Oct 15; 65(20):9406-14. PubMed ID: 16230404
    [Abstract] [Full Text] [Related]

  • 6. Cells resistant to HTI-286 do not overexpress P-glycoprotein but have reduced drug accumulation and a point mutation in alpha-tubulin.
    Loganzo F, Hari M, Annable T, Tan X, Morilla DB, Musto S, Zask A, Kaplan J, Minnick AA, May MK, Ayral-Kaloustian S, Poruchynsky MS, Fojo T, Greenberger LM.
    Mol Cancer Ther; 2004 Oct 15; 3(10):1319-27. PubMed ID: 15486199
    [Abstract] [Full Text] [Related]

  • 7. Two photoaffinity analogues of the tripeptide, hemiasterlin, exclusively label alpha-tubulin.
    Nunes M, Kaplan J, Wooters J, Hari M, Minnick AA, May MK, Shi C, Musto S, Beyer C, Krishnamurthy G, Qiu Y, Loganzo F, Ayral-Kaloustian S, Zask A, Greenberger LM.
    Biochemistry; 2005 May 10; 44(18):6844-57. PubMed ID: 15865430
    [Abstract] [Full Text] [Related]

  • 8. Differential regulation of the cytotoxicity activity of paclitaxel by orobol and platelet derived growth factor in human ovarian carcinoma cells.
    Isonishi S, Saitou M, Saitou M, Yasuda M, Tanaka T.
    Oncol Rep; 2007 Jul 10; 18(1):195-201. PubMed ID: 17549368
    [Abstract] [Full Text] [Related]

  • 9. Potent inhibition of tubulin polymerisation and proliferation of paclitaxel-resistant 1A9PTX22 human ovarian cancer cells by albendazole.
    Chu SW, Badar S, Morris DL, Pourgholami MH.
    Anticancer Res; 2009 Oct 10; 29(10):3791-6. PubMed ID: 19846910
    [Abstract] [Full Text] [Related]

  • 10. Intra-allelic suppression of a mutation that stabilizes microtubules and confers resistance to colcemid.
    Wang Y, Veeraraghavan S, Cabral F.
    Biochemistry; 2004 Jul 20; 43(28):8965-73. PubMed ID: 15248754
    [Abstract] [Full Text] [Related]

  • 11. Taccalonolides E and A: Plant-derived steroids with microtubule-stabilizing activity.
    Tinley TL, Randall-Hlubek DA, Leal RM, Jackson EM, Cessac JW, Quada JC, Hemscheidt TK, Mooberry SL.
    Cancer Res; 2003 Jun 15; 63(12):3211-20. PubMed ID: 12810650
    [Abstract] [Full Text] [Related]

  • 12. Altered levels and regulation of stathmin in paclitaxel-resistant ovarian cancer cells.
    Balachandran R, Welsh MJ, Day BW.
    Oncogene; 2003 Dec 04; 22(55):8924-30. PubMed ID: 14654788
    [Abstract] [Full Text] [Related]

  • 13. Resistance mechanisms in human sarcoma mutants derived by single-step exposure to paclitaxel (Taxol).
    Dumontet C, Duran GE, Steger KA, Beketic-Oreskovic L, Sikic BI.
    Cancer Res; 1996 Mar 01; 56(5):1091-7. PubMed ID: 8640766
    [Abstract] [Full Text] [Related]

  • 14. Cross-resistance to the synthetic retinoid CD437 in a paclitaxel-resistant human ovarian carcinoma cell line is independent of the overexpression of retinoic acid receptor-gamma.
    Kumar A, Soprano DR, Parekh HK.
    Cancer Res; 2001 Oct 15; 61(20):7552-5. PubMed ID: 11606393
    [Abstract] [Full Text] [Related]

  • 15. Analysis of tubulin isotypes and mutations from taxol-resistant cells by combined isoelectrofocusing and mass spectrometry.
    Verdier-Pinard P, Wang F, Martello L, Burd B, Orr GA, Horwitz SB.
    Biochemistry; 2003 May 13; 42(18):5349-57. PubMed ID: 12731876
    [Abstract] [Full Text] [Related]

  • 16. Expression of beta-tubulin isotypes in human ovarian carcinoma xenografts and in a sub-panel of human cancer cell lines from the NCI-Anticancer Drug Screen: correlation with sensitivity to microtubule active agents.
    Nicoletti MI, Valoti G, Giannakakou P, Zhan Z, Kim JH, Lucchini V, Landoni F, Mayo JG, Giavazzi R, Fojo T.
    Clin Cancer Res; 2001 Sep 13; 7(9):2912-22. PubMed ID: 11555610
    [Abstract] [Full Text] [Related]

  • 17. Synthesis and biological activity of analogues of the antimicrotubule agent N,beta,beta-trimethyl-L-phenylalanyl-N(1)-[(1S,2E)-3-carboxy-1-isopropylbut-2-enyl]- N(1),3-dimethyl-L-valinamide (HTI-286).
    Zask A, Birnberg G, Cheung K, Kaplan J, Niu C, Norton E, Suayan R, Yamashita A, Cole D, Tang Z, Krishnamurthy G, Williamson R, Khafizova G, Musto S, Hernandez R, Annable T, Yang X, Discafani C, Beyer C, Greenberger LM, Loganzo F, Ayral-Kaloustian S.
    J Med Chem; 2004 Sep 09; 47(19):4774-86. PubMed ID: 15341492
    [Abstract] [Full Text] [Related]

  • 18. Mutations at leucine 215 of beta-tubulin affect paclitaxel sensitivity by two distinct mechanisms.
    Wang Y, Yin S, Blade K, Cooper G, Menick DR, Cabral F.
    Biochemistry; 2006 Jan 10; 45(1):185-94. PubMed ID: 16388594
    [Abstract] [Full Text] [Related]

  • 19. Cyclostreptin (FR182877), an antitumor tubulin-polymerizing agent deficient in enhancing tubulin assembly despite its high affinity for the taxoid site.
    Edler MC, Buey RM, Gussio R, Marcus AI, Vanderwal CD, Sorensen EJ, Díaz JF, Giannakakou P, Hamel E.
    Biochemistry; 2005 Aug 30; 44(34):11525-38. PubMed ID: 16114889
    [Abstract] [Full Text] [Related]

  • 20. SRC tyrosine kinase and multidrug resistance protein-1 inhibitions act independently but cooperatively to restore paclitaxel sensitivity to paclitaxel-resistant ovarian cancer cells.
    George JA, Chen T, Taylor CC.
    Cancer Res; 2005 Nov 15; 65(22):10381-8. PubMed ID: 16288028
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.